Drugs in the Pipeline – Invited Review ArticleThe NLRP3 Inflammasome as a Pharmacological TargetMarchetti, Carlo PhDAuthor Information Department of Medicine, University of Colorado Denver, Aurora, CO. Reprints: Carlo Marchetti, PhD, Department of Medicine, University of Colorado Denver, Aurora, CO 80045 (e-mail: firstname.lastname@example.org). The author reports no conflicts of interest. Journal of Cardiovascular Pharmacology: October 2019 - Volume 74 - Issue 4 - p 285-296 doi: 10.1097/FJC.0000000000000718 Buy Metrics Abstract NLRP3 is a cytosolic receptor member of the nucleotide-binding oligomerization domain NOD-like receptor family that surveys the intracellular environment for the presence of infection, pathogens, and metabolic alarms. Although the surveillance activity of NLRP3 is required to protect the host from several pathogens, uncontrolled activity can be detrimental to the host. Pharmacological and genetic strategies limiting NLRP3 inflammasome activation have been shown to be beneficial in a wide range of experimental models, from common pathologies such as arthritis, cardiovascular disease, and metabolic syndromes to rare genetic disorders such as cryopyrin-associated periodic syndrome. Thus, compounds that prevent NLRP3 inflammasome activation are of common interest with relevant therapeutic potential. The focus of this review is recent developments in NLRP3 inflammasome inhibitors. Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.